Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) has received a consensus rating of “Buy” from the ten brokerages that are covering the company, Analyst Ratings Network reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $509.75.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 4.06% on Thursday, hitting $243.35. 286,587 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a one year low of $38.90 and a one year high of $497.00. The stock’s 50-day moving average is $258.4 and its 200-day moving average is $273.4. The company’s market cap is $5.132 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.59) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-13.20 earnings per share for the current fiscal year.

ICPT has been the subject of a number of recent research reports. Analysts at Leerink Swann initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday. They set a “market perform” rating and a $270.00 price target on the stock. Separately, analysts at Nomura initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $294.00 price target on the stock. Finally, analysts at Summer Street initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, May 15th. They set a “buy” rating and a $650.00 price target on the stock.

In other Intercept Pharmaceuticals news, CMO David Shapiro sold 4,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $278.15, for a total transaction of $1,112,600.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.